Download PDF
Exp Clin Endocrinol Diabetes 2018; 126(09): 570-576
DOI: 10.1055/s-0043-120570
Article
© Georg Thieme Verlag KG Stuttgart · New York

Prevalence and Progression Rate of Diabetic Retinopathy in Type 2 Diabetes Patients in Correlation with the Duration of Diabetes

Margarete Voigt
1   Department of Internal Medicine III, University Hospital Jena, Jena, Germany
,
Sebastian Schmidt
1   Department of Internal Medicine III, University Hospital Jena, Jena, Germany
,
Thomas Lehmann
3   Department of Medical Statistics, University Hospital Jena, Information and Documentation, Jena, Germany
,
Benjamin Köhler
1   Department of Internal Medicine III, University Hospital Jena, Jena, Germany
,
Christof Kloos
1   Department of Internal Medicine III, University Hospital Jena, Jena, Germany
,
Ulrich A. Voigt
2   Department of Ophthalmology, University Hospital Jena, Jena, Germany
,
Daniel Meller
2   Department of Ophthalmology, University Hospital Jena, Jena, Germany
,
Gunter Wolf
1   Department of Internal Medicine III, University Hospital Jena, Jena, Germany
,
Ulrich A. Müller
1   Department of Internal Medicine III, University Hospital Jena, Jena, Germany
,
Nicolle Müller
1   Department of Internal Medicine III, University Hospital Jena, Jena, Germany
› Author Affiliations
Further Information

Publication History

received 07 June 2017
revised13 August 2017

accepted 29 September 2017

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

Correction to:

Correction: Prevalence and Progression Rate of Diabetic Retinopathy in Type 2 Diabetes Patients in Correlation with the Duration of DiabetesExp Clin Endocrinol Diabetes 2018; 126(09): e2-e2
DOI: 10.1055/a-0757-3796

Abstract

Aims We examined prevalence and progression of retinopathy in dependence on diabetes duration in order to estimate the probability of progression.

Patients/Methods In a retrospective cohort-analysis from an academic outpatient department of endocrinology and metabolic diseases we analyzed 17461 consultations of 4513 patients with DM2 from 1987 to 2014. 50.3% of the patients (n=2272) had at least one documented result of funduscopy.

Results 25.8% of the patients had retinopathy (20.2% non-proliferative, 4.7% proliferative, 0.7% were not classified, 0.1% blindness). The prevalence of retinopathy in dependence on diabetes duration was 1.1% at diagnosis, 6.6% after 0<5 years, 12% after 5<10 years, 24% after 10<15 years, 39.9% after 15<20 years, 52.7% after 20<25 years, 58.7% after 25<30 years and 63% after ≥30 years. In a subset of 586 (25.7%) patients with retinal photography of 3 consecutive years 7.0% showed deterioration after one and 12.2% after two years; 2.6% improved after one and 2.8% after two years. 201 (34.3%) of this group had<10 years diabetes and lower deterioration (4.5% worsened after one and 9.5% after two years). Their retinopathy mainly transformed from no retinopathy to non-proliferative. Four patients (2.0%) developed proliferative retinopathy.

Conclusions/Interpretations Within the first 10 years of diabetes duration, the prevalence of retinopathy is low and the progression infrequent. Most patients have a non-proliferative form which can be reversible and rarely requires interventions. Patients with DM2 without retinopathy and good glycaemic control do not run into additional risk from expanding funduscopy intervals to biennial.

Key words

Diabetes mellitus type 2 - Diabetic retinopathy - Prevalence - Diabetes duration - Screening interval

Supplementary Material

 

  • References

  • 1 Kollias AN, Ulbig MW. Diabetic retinopathy: Early diagnosis and effective treatment. Deutsches Arzteblatt International 2010; 107: 75
    PubMedGoogle Scholar
  • 2 Zhang X, Saaddine JB, Chou CF. et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. Jama 2010; 304: 649-656
    CrossrefPubMedGoogle Scholar
  • 3 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376: 124-136
    CrossrefPubMedGoogle Scholar
  • 4 Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: Providing evidence, raising awareness and promoting action. Diabetes research and clinical practice 2010; 87: 2-3
    CrossrefPubMedGoogle Scholar
  • 5 Jonsson B, Board C-A. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002; 45: S5-S12
    CrossrefPubMedGoogle Scholar
  • 6 Raum P, Lamparter J, Ponto KA. et al. Prevalence and cardiovascular associations of diabetic retinopathy and maculopathy: Results from the gutenberg health study. PloS one 2015; 10: e0127188
    CrossrefPubMedGoogle Scholar
  • 7 Group ETDRSR. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology 1991; 98: 786-806
    CrossrefPubMedGoogle Scholar
  • 8 Wilkinson CP, Ferris 3rd FL, Klein RE. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682
    CrossrefPubMedGoogle Scholar
  • 9 Nentwich M, Lemmen K, Ulbig M. Stadieneinteilung und Therapie der diabetischen Retinopathie und Makulopathie. Z prakt Augenheilk 2010; 31: 491-499
    PubMedGoogle Scholar
  • 10 Looker HC, Nyangoma SO, Cromie DT. et al. Predicted impact of extending the screening interval for diabetic retinopathy: The Scottish Diabetic Retinopathy Screening programme. Diabetologia 2013; 56: 1716-1725
    CrossrefPubMedGoogle Scholar
  • 11 Zavrelova H, Hoekstra T, Alssema M. et al. Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system west-friesland, the Netherlands. Diabetes care 2011; 34: 867-872
    CrossrefPubMedGoogle Scholar
  • 12 Hesse L, Grüsser M, Hoffstadt K. et al. Populationsbezogene Erhebung zur diabetischen Retinopathie in Wolfsburg. Der Ophthalmologe 2001; 98: 1065-1068
    CrossrefPubMedGoogle Scholar
  • 13 Blum PDM, Kloos C, Müller N. et al. Prävalenz der diabetischen Retinopathie. Der Ophthalmologe 2007; 104: 499-504
    CrossrefPubMedGoogle Scholar
  • 14 Muller N, Heller T, Freitag MH. et al. Healthcare utilization of people with type 2 diabetes in Germany: An analysis based on health insurance data. Diabetic medicine: a journal of the British Diabetic Association 2015; 32: 951-957
    CrossrefPubMedGoogle Scholar
  • 15 Hagen B, Altenhofen L, Groos S. et al. Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme (ed.): Qualitätssicherungsbericht 2012 Disease-Management-Programme in Nordrhein. Düsseldorf: Nordrheinische Gemeinsame Einrichtung; 2013
    Google Scholar
  • 16 Hammes HP, Welp R, Kempe HP. et al. Risk Factors for Retinopathy and DME in Type 2 Diabetes-Results from the German/Austrian DPV Database. PloS one 2015; 10: e0132492
    CrossrefPubMedGoogle Scholar
  • 17 Kloos C, Muller N, Wolf G. et al. Better HbA1c and blood pressure control in patients with diabetes mellitus treated at a primary health care level 10 years after initiation of a diabetes quality improvement program. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association 2011; 119: 459-462
    PubMedGoogle Scholar
  • 18 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. The New England Journal of Medicine 1993; 329: 977-986
    CrossrefPubMedGoogle Scholar
  • 19 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
    CrossrefPubMedGoogle Scholar
  • 20 Klein R, Klein BE. Are individuals with diabetes seeing better?: a long-term epidemiological perspective. Diabetes 2010; 59: 1853-1860
    CrossrefPubMedGoogle Scholar
  • 21 Bachmann MO, Nelson SJ. Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. Journal of Epidemiology and Community Health 1998; 52: 45-52
    CrossrefPubMedGoogle Scholar
  • 22 Mehlsen J, Erlandsen M, Poulsen PL. et al. Individualized optimization of the screening interval for diabetic retinopathy: A new model. Acta ophthalmologica 2012; 90: 109-114
    CrossrefPubMedGoogle Scholar
  • 23 Aspelund T, Thornorisdottir O, Olafsdottir E. et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 2011; 54: 2525-2532
    CrossrefPubMedGoogle Scholar
  • 24 Agardh E, Tababat-Khani P. Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes care 2011; 34: 1318-1319
    CrossrefPubMedGoogle Scholar
  • 25 Younis N, Broadbent DM, Vora JP. Liverpool Diabetic Eye S. et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: A cohort study. Lancet 2003; 361: 195-200
    CrossrefPubMedGoogle Scholar
  • 26 Jones CD, Greenwood RH, Misra A. et al. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes care 2012; 35: 592-596
    CrossrefPubMedGoogle Scholar
  • 27 Porta M, Maurino M, Severini S. et al. Clinical characteristics influence screening intervals for diabetic retinopathy. Diabetologia 2013; 56: 2147-2152
    CrossrefPubMedGoogle Scholar
  • 28 Thomas RL, Dunstan F, Luzio SD. et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. Bmj 2012; 344: e874
    CrossrefPubMedGoogle Scholar
  • 29 Olafsdottir E, Stefansson E. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. The British journal of ophthalmology 2007; 91: 1599-1601
    CrossrefPubMedGoogle Scholar
  • 30 Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. Jama 2000; 283: 889-896
    CrossrefPubMedGoogle Scholar
  • 31 Yau JW, Rogers SL, Kawasaki R. et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes care 2012; 35: 556-564
    CrossrefPubMedGoogle Scholar
  • 32 Hemmingsen B, Lund SS, Gluud C. et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. The Cochrane database of systematic reviews 2013; 11: CD008143
    PubMedGoogle Scholar
  • 33 Fullerton DA, Sundt TM. Process versus outcome: the sugar window. The Annals of thoracic surgery 2014; 98: 1902-1904
    CrossrefPubMedGoogle Scholar